Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

ConclusionThese results further support the efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine.Trial RegistrationClinicalTrials.gov Identifiers: ACHIEVE I: NCT02828020; ACHIEVE II: NCT02867709

http://link.springer.com/10.1007/s40120-021-00234-7

Source: Neurology and Therapy - February 20, 2021 Category: Neurology Source Type: research